-
First Patient Enrolled in SNR High Dose High Intensity Study with MindMaze Therapeutics
MindMaze Therapeutics Holding SA (SIX: MMTX), today announced that the SwissNeuroRehab Consortium (www.swissneurorehab.ch) has enrolled its first patient in the High-Dose, High-Intensity (HDHI) neurorehabilitation study – Advancing At-Home Reimbursement Strategy in Europe. The study is a multicenter feasibility and implementation project evaluating whether HDHI neurorehabilitation can be delivered sustainably within a continuum-of-care framework. The study is powered by MindMaze’s precision neurotherapeutic platform (including MindMotionGO, Izar, and Companion). The study targets 300 minutes of active training per week, spanning a 4-6 week inpatient phase, an 8-12 week outpatient/home phase, and a follow-up at 15 months from inclusion. Recruitment is active at Lausanne University Hospital (CHUV), Institution de Lavigny, Rehaklinik Valens, Swiss…
-
SWISSNEUROREHAB: first Patient Public Involvement (PPI) Day on March 31st 2025
Integrating patient perspective into SwissNeuroRehab. The SwissNeurorehab (SNR) project aims at improving the autonomy of people undergoing neurorehabilitation and to facilitate their return to their social and professional life, at their best conditions. To do that, SNR will develop and assess the efficacy and efficiency of a new model of care for neurorehabilitation of acquired brain injury (ABI) and spinal cord injury (SCI) that improves the continuum of care and boost therapy delivery via neurotechnologies and Digital Therapeutics (DTx). To support patient involvement and by then increase the value of the future new model of care from the point of view of patients and their relatives, SwissNeuroRehab has created a…
